Quotient (NASDAQ:QTNT) Upgraded by BidaskClub to “Buy”

Quotient (NASDAQ:QTNT) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Tuesday, January 29th.

A number of other brokerages also recently issued reports on QTNT. ValuEngine raised Quotient from a “hold” rating to a “buy” rating in a research note on Thursday, December 13th. Zacks Investment Research raised Quotient from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th.

NASDAQ QTNT opened at $9.40 on Tuesday. Quotient has a one year low of $3.69 and a one year high of $9.99. The company has a debt-to-equity ratio of 4.95, a current ratio of 6.87 and a quick ratio of 6.05. The firm has a market capitalization of $608.04 million, a P/E ratio of -4.65 and a beta of 1.31.

Quotient (NASDAQ:QTNT) last issued its earnings results on Thursday, January 31st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). The business had revenue of $6.72 million during the quarter, compared to analyst estimates of $6.20 million. On average, sell-side analysts forecast that Quotient will post -1.93 earnings per share for the current year.

In other Quotient news, Director Frederick Hallsworth purchased 10,000 shares of the stock in a transaction dated Tuesday, December 11th. The stock was acquired at an average cost of $6.50 per share, for a total transaction of $65,000.00. Following the acquisition, the director now owns 55,091 shares in the company, valued at approximately $358,091.50. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Life Sciences Maste Perceptive purchased 2,000,000 shares of the stock in a transaction dated Friday, December 7th. The shares were acquired at an average price of $6.50 per share, with a total value of $13,000,000.00. The disclosure for this purchase can be found here. 17.40% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Casdin Capital LLC purchased a new position in shares of Quotient during the 4th quarter worth $1,989,000. PEAK6 Investments LLC grew its holdings in shares of Quotient by 398.7% during the 4th quarter. PEAK6 Investments LLC now owns 71,769 shares of the company’s stock worth $439,000 after purchasing an additional 57,379 shares during the period. Hudson Bay Capital Management LP grew its holdings in shares of Quotient by 7.5% during the 4th quarter. Hudson Bay Capital Management LP now owns 860,000 shares of the company’s stock worth $5,263,000 after purchasing an additional 60,000 shares during the period. SlateStone Wealth LLC purchased a new position in shares of Quotient during the 4th quarter worth $91,000. Finally, Bellevue Group AG grew its holdings in shares of Quotient by 15.5% during the 4th quarter. Bellevue Group AG now owns 833,619 shares of the company’s stock worth $5,102,000 after purchasing an additional 111,761 shares during the period. Institutional investors and hedge funds own 61.39% of the company’s stock.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Featured Story: How does the Federal Reserve determine interest rates?

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply